EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Organogenesis Holdings's enterprise value is $419.4 Mil.
Organogenesis Holdings's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was $448.4 Mil. Therefore, Organogenesis Holdings's EV-to-Revenue for today is 0.94.
The historical rank and industry rank for Organogenesis Holdings's EV-to-Revenue or its related term are showing as below:
ORGO'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.6 Med: 1.86 Max: 59.93
Current: 0.94
During the past 9 years, the highest EV-to-Revenue of Organogenesis Holdings was 59.93. The lowest was 0.60. And the median was 1.86.
ORGO's EV-to-Revenue is ranked better than 81.84% of 991
companies
in the Drug Manufacturers industry
Industry Median: 2.45
vs ORGO: 0.94
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Organogenesis Holdings's EV-to-Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, Organogenesis Holdings's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organogenesis Holdings's EV-to-Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Organogenesis Holdings's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Organogenesis Holdings's EV-to-Revenue falls into.
Organogenesis Holdings's current Enterprise Value is $419.4 Mil.
Organogenesis Holdings's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $448.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organogenesis Holdings's share price for today is $2.99.
Organogenesis Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.38.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organogenesis Holdings EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Organogenesis Holdings's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced wound care, surgical and sports medicine markets. Its product category includes Advanced Wound Care and Surgical and Sports Medicine. It has single operating segment which has regenerative medicine. The company generates maximum revenue from Advanced Wound Care products. Some of its products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, Dermagraft and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ORGO has been successfully added to your 